LFWD Lifeward Ltd.
Company Updates ·
The board appointed Ronen Tsimerman as chief financial officer, effective November 1, 2026. His employment agreement is subject to shareholder approval of a renewed compensation policy.
A September 2026 investor presentation filed as Exhibit 99.1 sets out the company's product timeline, its Oramed-linked oral delivery program and its reported cash and revenue.
Mark Grant leaves as president, chief executive and director effective August 31, 2026, and Josh Hexter becomes interim chief executive on September 1. Rami Aviram is named chief financial officer effective November 1, 2026.
Lifeward reported a net loss of $11.5 million for the quarter and said a July 6, 2026 financing could provide up to $11.2 million in growth capital.
The notes carry 8.0% interest and a $5.40 conversion price. The second tranche depends on ReWalk sales growth or a share price of $13.80 or higher.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $22.0 million | $25.7 million |
| Research and development | $3.2 million | $4.6 million |
| Net income (loss) | -$19.9 million | -$28.9 million |
| Cash from operations | -$16.8 million | -$21.7 million |
| Cash and equivalents | $2.2 million | $6.7 million |
Our latest story on this, dated Jun 30, 2026: "Lifeward amends senior secured convertible notes tied to Oramed". The story links the filing or release it is based on. Read the story.
Lifeward Ltd. trades under the ticker LFWD on NASDAQ.
Lifeward Ltd. is listed on NASDAQ.
Our directory records Lifeward Ltd. under United States.
aibio.space lists Lifeward Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
$22.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Lifeward Ltd. reported a net loss of $19.9 million for the fiscal year ended Dec 31, 2025, and used $16.8 million of cash in operations, per its annual report to the SEC.
$3.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
$9.4 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Lifeward, dated Oct 27, 2026: "Lifeward names Ronen Tsimerman chief financial officer". The board appointed Ronen Tsimerman as chief financial officer, effective November 1, 2026. His employment agreement is subject to shareholder approval of a renewed compensation policy. Source.
Press Follow on this page to add Lifeward to your Following list, or subscribe to the aibio.space newsletter. We have published 5 stories naming Lifeward so far, in Company Updates, Debt Financing.
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio